<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p194" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_194{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_194{left:306px;bottom:30px;}
#t3_194{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_194{left:346px;bottom:30px;}
#t5_194{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_194{left:517px;bottom:30px;}
#t7_194{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_194{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_194{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_194{left:1115px;bottom:27px;letter-spacing:0.23px;}
#tb_194{left:35px;bottom:777px;letter-spacing:0.14px;word-spacing:0.05px;}
#tc_194{left:550px;bottom:777px;}
#td_194{left:565px;bottom:777px;}
#te_194{left:35px;bottom:754px;letter-spacing:0.17px;word-spacing:0.02px;}
#tf_194{left:35px;bottom:731px;letter-spacing:0.11px;word-spacing:0.08px;}
#tg_194{left:376px;bottom:731px;}
#th_194{left:391px;bottom:731px;letter-spacing:0.02px;word-spacing:0.17px;}
#ti_194{left:35px;bottom:707px;letter-spacing:0.11px;word-spacing:0.22px;}
#tj_194{left:35px;bottom:684px;letter-spacing:0.15px;word-spacing:0.04px;}
#tk_194{left:35px;bottom:661px;letter-spacing:0.15px;word-spacing:0.04px;}
#tl_194{left:35px;bottom:638px;letter-spacing:0.13px;word-spacing:0.05px;}
#tm_194{left:35px;bottom:614px;letter-spacing:0.05px;word-spacing:0.29px;}
#tn_194{left:35px;bottom:591px;letter-spacing:0.06px;word-spacing:0.27px;}
#to_194{left:35px;bottom:568px;letter-spacing:0.08px;word-spacing:0.1px;}
#tp_194{left:35px;bottom:545px;letter-spacing:0.1px;word-spacing:0.09px;}
#tq_194{left:35px;bottom:522px;letter-spacing:0.16px;word-spacing:0.03px;}
#tr_194{left:35px;bottom:498px;letter-spacing:0.18px;word-spacing:0.01px;}
#ts_194{left:288px;bottom:506px;letter-spacing:-0.01px;}
#tt_194{left:35px;bottom:459px;letter-spacing:0.04px;word-spacing:0.55px;}
#tu_194{left:35px;bottom:436px;letter-spacing:0.09px;word-spacing:0.1px;}
#tv_194{left:35px;bottom:413px;letter-spacing:0.06px;word-spacing:1.34px;}
#tw_194{left:204px;bottom:420px;letter-spacing:-0.01px;}
#tx_194{left:227px;bottom:413px;letter-spacing:0.22px;word-spacing:-0.03px;}
#ty_194{left:35px;bottom:390px;letter-spacing:0.08px;word-spacing:0.23px;}
#tz_194{left:35px;bottom:366px;letter-spacing:0.14px;word-spacing:0.05px;}
#t10_194{left:35px;bottom:343px;letter-spacing:-0.12px;}
#t11_194{left:100px;bottom:351px;letter-spacing:-0.01px;}
#t12_194{left:123px;bottom:343px;letter-spacing:0.01px;word-spacing:0.28px;}
#t13_194{left:35px;bottom:320px;letter-spacing:0.14px;word-spacing:0.05px;}
#t14_194{left:35px;bottom:297px;letter-spacing:0.02px;word-spacing:0.17px;}
#t15_194{left:35px;bottom:273px;letter-spacing:0.1px;word-spacing:0.09px;}
#t16_194{left:218px;bottom:281px;letter-spacing:-0.01px;}
#t17_194{left:241px;bottom:273px;letter-spacing:0.15px;word-spacing:0.03px;}
#t18_194{left:35px;bottom:250px;letter-spacing:0.07px;word-spacing:0.36px;}
#t19_194{left:293px;bottom:250px;}
#t1a_194{left:310px;bottom:250px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1b_194{left:35px;bottom:227px;letter-spacing:0.05px;}
#t1c_194{left:75px;bottom:235px;letter-spacing:-0.01px;}
#t1d_194{left:98px;bottom:227px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1e_194{left:35px;bottom:204px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1f_194{left:35px;bottom:181px;letter-spacing:0.11px;word-spacing:0.08px;}
#t1g_194{left:35px;bottom:157px;letter-spacing:0.08px;word-spacing:0.25px;}
#t1h_194{left:35px;bottom:134px;letter-spacing:0.01px;word-spacing:0.17px;}
#t1i_194{left:163px;bottom:142px;letter-spacing:-0.01px;}
#t1j_194{left:35px;bottom:94px;letter-spacing:0.08px;word-spacing:0.25px;}
#t1k_194{left:35px;bottom:71px;letter-spacing:0.01px;word-spacing:0.35px;}
#t1l_194{left:420px;bottom:78px;letter-spacing:-0.01px;}
#t1m_194{left:444px;bottom:71px;letter-spacing:-0.03px;word-spacing:0.21px;}
#t1n_194{left:618px;bottom:777px;letter-spacing:0.05px;word-spacing:0.14px;}
#t1o_194{left:867px;bottom:777px;}
#t1p_194{left:884px;bottom:777px;letter-spacing:0.15px;word-spacing:0.04px;}
#t1q_194{left:618px;bottom:754px;letter-spacing:0.08px;word-spacing:0.29px;}
#t1r_194{left:618px;bottom:731px;letter-spacing:0.06px;word-spacing:0.28px;}
#t1s_194{left:618px;bottom:707px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1t_194{left:618px;bottom:684px;letter-spacing:0.2px;word-spacing:-0.01px;}
#t1u_194{left:772px;bottom:684px;}
#t1v_194{left:788px;bottom:684px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1w_194{left:618px;bottom:661px;letter-spacing:0.13px;word-spacing:0.05px;}
#t1x_194{left:618px;bottom:638px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1y_194{left:618px;bottom:614px;letter-spacing:0.05px;word-spacing:0.13px;}
#t1z_194{left:618px;bottom:591px;letter-spacing:0.09px;word-spacing:0.25px;}
#t20_194{left:618px;bottom:568px;letter-spacing:0.12px;word-spacing:0.07px;}
#t21_194{left:618px;bottom:545px;letter-spacing:0.13px;word-spacing:0.06px;}
#t22_194{left:790px;bottom:552px;letter-spacing:-0.01px;}
#t23_194{left:813px;bottom:545px;letter-spacing:-0.06px;word-spacing:0.25px;}
#t24_194{left:618px;bottom:522px;letter-spacing:0.08px;word-spacing:0.26px;}
#t25_194{left:618px;bottom:498px;letter-spacing:0.11px;word-spacing:0.24px;}
#t26_194{left:618px;bottom:475px;letter-spacing:0.07px;word-spacing:-0.19px;}
#t27_194{left:1051px;bottom:483px;letter-spacing:-0.01px;}
#t28_194{left:1076px;bottom:475px;letter-spacing:0.22px;word-spacing:-0.65px;}
#t29_194{left:618px;bottom:452px;letter-spacing:0.08px;word-spacing:0.11px;}
#t2a_194{left:618px;bottom:430px;letter-spacing:0.05px;word-spacing:0.25px;}
#t2b_194{left:618px;bottom:407px;letter-spacing:0.15px;word-spacing:0.04px;}
#t2c_194{left:618px;bottom:366px;letter-spacing:0.07px;word-spacing:0.12px;}
#t2d_194{left:618px;bottom:343px;letter-spacing:0.11px;word-spacing:0.08px;}
#t2e_194{left:618px;bottom:320px;letter-spacing:-0.05px;word-spacing:0.55px;}
#t2f_194{left:856px;bottom:327px;letter-spacing:-0.01px;}
#t2g_194{left:880px;bottom:320px;letter-spacing:0.07px;word-spacing:0.12px;}
#t2h_194{left:618px;bottom:297px;letter-spacing:0.11px;word-spacing:0.08px;}
#t2i_194{left:618px;bottom:256px;letter-spacing:0.09px;word-spacing:0.23px;}
#t2j_194{left:618px;bottom:233px;letter-spacing:0.06px;word-spacing:0.4px;}
#t2k_194{left:618px;bottom:210px;letter-spacing:0.1px;word-spacing:0.09px;}
#t2l_194{left:687px;bottom:210px;}
#t2m_194{left:704px;bottom:210px;letter-spacing:0.1px;word-spacing:0.09px;}
#t2n_194{left:1077px;bottom:217px;letter-spacing:-0.01px;}
#t2o_194{left:1100px;bottom:210px;letter-spacing:-0.06px;}
#t2p_194{left:618px;bottom:187px;letter-spacing:0.07px;word-spacing:0.12px;}
#t2q_194{left:618px;bottom:163px;letter-spacing:0.12px;word-spacing:0.06px;}
#t2r_194{left:1056px;bottom:163px;}
#t2s_194{left:1072px;bottom:163px;letter-spacing:0.23px;word-spacing:-0.05px;}
#t2t_194{left:618px;bottom:140px;letter-spacing:0.3px;word-spacing:-0.11px;}
#t2u_194{left:962px;bottom:148px;letter-spacing:-0.01px;}
#t2v_194{left:985px;bottom:140px;letter-spacing:0.01px;word-spacing:0.18px;}
#t2w_194{left:618px;bottom:117px;letter-spacing:0.06px;word-spacing:0.39px;}
#t2x_194{left:618px;bottom:94px;letter-spacing:0.06px;word-spacing:0.4px;}
#t2y_194{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_194{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_194{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_194{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_194{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_194{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_194{font-size:17px;font-family:Arial-ItalicMT_kb;color:#000;}
.s6_194{font-size:11px;font-family:ArialMT_5tg;color:#000;}
.s7_194{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts194" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_kb;
	src: url("fonts/Arial-ItalicMT_kb.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg194Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg194" style="-webkit-user-select: none;"><object width="1210" height="935" data="194/194.svg" type="image/svg+xml" id="pdf194" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_194" class="t s0_194">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_194" class="t s1_194">© </span>
<span id="t3_194" class="t s0_194">(NCCN </span>
<span id="t4_194" class="t s1_194">© </span>
<span id="t5_194" class="t s0_194">), All rights reserved. NCCN Guidelines </span>
<span id="t6_194" class="t s1_194">® </span>
<span id="t7_194" class="t s0_194">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_194" class="t s2_194">NCCN Guidelines Version 4.2024 </span>
<span id="t9_194" class="t s2_194">Head and Neck Cancers </span>
<span id="ta_194" class="t s3_194">MS-53 </span>
<span id="tb_194" class="t s4_194">those patients with a tumor PD-L1 expression level of 1% or more (</span><span id="tc_194" class="t s5_194">n </span><span id="td_194" class="t s4_194">= </span>
<span id="te_194" class="t s4_194">149) (8.7 vs. 4.6 months; HR, 0.55; 95% CI, 0.36–0.83). In patients with </span>
<span id="tf_194" class="t s4_194">tumor PD-L1 expression level less than 1% (</span><span id="tg_194" class="t s5_194">n </span><span id="th_194" class="t s4_194">= 111), no OS advantage </span>
<span id="ti_194" class="t s4_194">was demonstrated for the nivolumab-treated patients (5.7 vs. 5.8 </span>
<span id="tj_194" class="t s4_194">months; HR, 0.89; 95% CI, 0.54–1.45). Grade 3 or 4 treatment-related </span>
<span id="tk_194" class="t s4_194">adverse events occurred in 13.1% of patients who received nivolumab, </span>
<span id="tl_194" class="t s4_194">compared to 35.1% of patients who received standard therapy. These </span>
<span id="tm_194" class="t s4_194">results indicate that nivolumab prolongs survival in patients with </span>
<span id="tn_194" class="t s4_194">recurrent or metastatic squamous cell H&amp;N cancer that has progressed </span>
<span id="to_194" class="t s4_194">after platinum-based chemotherapy, relative to patients who receive </span>
<span id="tp_194" class="t s4_194">standard single-agent systemic therapy. There are two FDA-approved </span>
<span id="tq_194" class="t s4_194">dosing regimens for nivolumab for treatment of SCCHN: 240 mg every 2 </span>
<span id="tr_194" class="t s4_194">weeks or 480 mg every 4 weeks. </span>
<span id="ts_194" class="t s6_194">667 </span>
<span id="tt_194" class="t s4_194">Pembrolizumab was initially studied at a dose of 10 mg/kg given every 2 </span>
<span id="tu_194" class="t s4_194">weeks in the SCCHN cohort of the KEYNOTE-012 trial, and clinical </span>
<span id="tv_194" class="t s4_194">activity was identified. </span>
<span id="tw_194" class="t s6_194">668 </span>
<span id="tx_194" class="t s4_194">A lower, fixed-dose schedule using </span>
<span id="ty_194" class="t s4_194">pembrolizumab 200 mg every 3 weeks was subsequently assessed in a </span>
<span id="tz_194" class="t s4_194">phase 1b expansion cohort of 132 patients with recurrent or metastatic </span>
<span id="t10_194" class="t s4_194">SCCHN. </span>
<span id="t11_194" class="t s6_194">669 </span>
<span id="t12_194" class="t s4_194">At 6 months, the OS rate was 59%, and the PFS was 23%, </span>
<span id="t13_194" class="t s4_194">with an ORR of 18%. Observed responses appeared durable, although </span>
<span id="t14_194" class="t s4_194">the follow-up was limited (median, 9 months). Pembrolizumab was also </span>
<span id="t15_194" class="t s4_194">generally well-tolerated. </span>
<span id="t16_194" class="t s6_194">668 </span>
<span id="t17_194" class="t s4_194">Pooled analyses after long-term follow-up of </span>
<span id="t18_194" class="t s4_194">the initial and expansion cohorts (</span><span id="t19_194" class="t s5_194">N </span><span id="t1a_194" class="t s4_194">= 192) showed a 1-year OS rate of </span>
<span id="t1b_194" class="t s4_194">38%. </span>
<span id="t1c_194" class="t s6_194">670 </span>
<span id="t1d_194" class="t s4_194">Among the 34 patients with a disease response, 85% of the </span>
<span id="t1e_194" class="t s4_194">responses lasted 6 months or longer, and 71% lasted 12 months or </span>
<span id="t1f_194" class="t s4_194">longer. The FDA has approved an alternate dosing regimen of </span>
<span id="t1g_194" class="t s4_194">pembrolizumab 400 mg every 6 weeks across all currently approved </span>
<span id="t1h_194" class="t s4_194">adult indications. </span>
<span id="t1i_194" class="t s6_194">671 </span>
<span id="t1j_194" class="t s4_194">Based on results of the phase Ib KEYNOTE-012 trial, pembrolizumab </span>
<span id="t1k_194" class="t s4_194">was evaluated in the phase III KEYNOTE-040 trial. </span>
<span id="t1l_194" class="t s6_194">637 </span>
<span id="t1m_194" class="t s4_194">Patients with </span>
<span id="t1n_194" class="t s4_194">recurrent or metastatic SCCHN (</span><span id="t1o_194" class="t s5_194">N </span><span id="t1p_194" class="t s4_194">= 495) were randomized to receive </span>
<span id="t1q_194" class="t s4_194">pembrolizumab or another systemic therapy (methotrexate, docetaxel, or </span>
<span id="t1r_194" class="t s4_194">cetuximab). Median OS was greater for the pembrolizumab arm </span>
<span id="t1s_194" class="t s4_194">compared to the standard-of-care arm (8.4 vs. 6.9 months; HR, 0.80; </span>
<span id="t1t_194" class="t s4_194">95% CI, 0.65–0.98; </span><span id="t1u_194" class="t s5_194">P </span><span id="t1v_194" class="t s4_194">= .016). When analyses were stratified by PD-L1 </span>
<span id="t1w_194" class="t s4_194">status, the results for OS were significantly better with pembrolizumab </span>
<span id="t1x_194" class="t s4_194">only for patients with tumors that have PD-L1 expression. Exploratory </span>
<span id="t1y_194" class="t s4_194">health-related QOL analyses showed that patients treated with </span>
<span id="t1z_194" class="t s4_194">pembrolizumab had stable functioning and symptoms through 15 weeks, </span>
<span id="t20_194" class="t s4_194">compared to the patients treated with standard of care, for whom a </span>
<span id="t21_194" class="t s4_194">decline was observed. </span>
<span id="t22_194" class="t s6_194">672 </span>
<span id="t23_194" class="t s4_194">Pembrolizumab monotherapy was also </span>
<span id="t24_194" class="t s4_194">evaluated for previously treated tumors with high microsatellite instability </span>
<span id="t25_194" class="t s4_194">(MSI-H)/mismatch repair deficiency (dMMR) in the phase II KEYNOTE- </span>
<span id="t26_194" class="t s4_194">158 basket trial, which included one patient with SCCHN. </span>
<span id="t27_194" class="t s6_194">673 </span>
<span id="t28_194" class="t s4_194">The ORR for </span>
<span id="t29_194" class="t s4_194">the entire sample (N = 233) was 34.3% (95% CI, 28.3%–40.8%), median </span>
<span id="t2a_194" class="t s4_194">PFS was 4.1 months (95% CI, 2.4–4.9), and median OS was 23.5 </span>
<span id="t2b_194" class="t s4_194">months (95% CI, 13.5 months–not reached). </span>
<span id="t2c_194" class="t s4_194">The nonrandomized phase II KEYNOTE-055 trial studied pembrolizumab </span>
<span id="t2d_194" class="t s4_194">in 171 patients with SCCHN that progressed following treatment with </span>
<span id="t2e_194" class="t s4_194">both a platinum and cetuximab. </span>
<span id="t2f_194" class="t s6_194">674 </span>
<span id="t2g_194" class="t s4_194">The ORR was 16% (95% CI, 11%– </span>
<span id="t2h_194" class="t s4_194">23%), and the mean duration of response was 8 months. </span>
<span id="t2i_194" class="t s4_194">Afatinib was compared to methotrexate in patients with recurrent or </span>
<span id="t2j_194" class="t s4_194">metastatic H&amp;N cancer who had progressed on or after platinum-based </span>
<span id="t2k_194" class="t s4_194">therapy (</span><span id="t2l_194" class="t s5_194">N </span><span id="t2m_194" class="t s4_194">= 483) in the phase III LUX-Head &amp; Neck 1 RCT. </span>
<span id="t2n_194" class="t s6_194">675 </span>
<span id="t2o_194" class="t s4_194">Patients </span>
<span id="t2p_194" class="t s4_194">randomized to receive afatinib had greater PFS compared to patients </span>
<span id="t2q_194" class="t s4_194">randomized to receive methotrexate (2.6 vs. 1.7 months; </span><span id="t2r_194" class="t s5_194">P </span><span id="t2s_194" class="t s4_194">= .03), but </span>
<span id="t2t_194" class="t s4_194">there were no significant differences for OS. </span>
<span id="t2u_194" class="t s6_194">675 </span>
<span id="t2v_194" class="t s4_194">A randomized phase II </span>
<span id="t2w_194" class="t s4_194">trial comparing afatinib to cetuximab in patients with recurrent or </span>
<span id="t2x_194" class="t s4_194">metastatic H&amp;N cancer who had progressed on or after platinum-based </span>
<span id="t2y_194" class="t s7_194">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
